



Figure S1

A




B




C



D



E




F





**Figure S2**



**Figure S3**




Figure S4








Figure S5

A



B



## Supplementary Figure Legends

**Figure S1. Hot spot mutation analysis reveals that cell line RS4;11 carries a wild-type *p53* and ALL-PO carries a missense mutation exon 7 of the *p53* gene.** Hot spot mutation analysis of *p53* in RS4;11 in (A) exon 5, (B) exon 6, (C) exon 7 and (D) exon 8. Mutation analysis of *p53* in ALL-PO in (E) exon 5, (F) exon 6, (G) exon 7 and (H) exon 8. Data shown is based on Sanger sequencing. Genomic DNA was isolated from each cell line using the DNeasy Blood & Tissue kit (Qiagen) according to the manufacturer's instructions. *p53* mutational hotspots were amplified by PCR using the following primers: Exon 5 FW-CTCTGTCTCCTTCCTTCTTCTACAG; exon 5 RV-CGTCTCTCCAGCCCCAGCTGCTCAC; exon 6 FW-CTGATTCCTCACTGATTGCTCTTAG; exon 6 RV-CAGAGACCCCAGTTGCAAACCAGAC; exon 7 FW-CCAAGGCGCACTGGCCTCATCTTGGGCTGTGTTATCTCCTAG; exon 7 RV-GGGGCACAGCAGGCCAGTGTGCAGGGTGGCAAAGTGGCTCCTGAC; exon 8 FW-GCTTCTCTTTTCTATCCTGAGTAG; exon 8 RV-ACCGTCTCTTGTCTGCTTGTCTTA, with PCR program: 2 min on 50°C; 10 min on 95°C; 15 sec on 95°C followed by 1 min on 60°C for 40 cycles. PCR Products were verified by gel electrophoresis and isolated using the QIAquick Gel Extraction kit (Qiagen) prior to sending the DNA out for Sanger sequencing, which was performed at the Utrecht sequencing facility.

**Figure S2. Time course analysis on the protein expression of the *p53* pathway in presence of Idasanutlin in *KMT2A-AFF1* ALL cells.** Western blot analysis on the expression of *p53*, *p53* acetylation at lysine 382, target gene *p21* and *MDM2* upon exposure to 0.5µM Idasanutlin in RS4;11 over a time course ranging from 30 minutes to 24 hours.  $\beta$ -actin (Abcam) was used as loading control.

**Figure S3. Effects of forced *p53* activity on the expression of the *p53* pathway in BEL-1 carrying either wild-type or mutated *p53*.** Western blot analysis showing the protein expression of *MDM2*, *p53* acetylation at lysine 382, *p53*, *p21* and cleaved *PARP* measured at 6 and 24 hours post doxycycline induction in the transduced BEL-1 cell line carrying doxycycline-inducible expression vectors either encoding wild-type or mutated (R248Q) *p53*. Housekeeping gene *GAPDH* was used as loading control. Note, this figure is a biological replicate of Figure 4A.

**Figure S4. Forced *p53* activation mildly induces apoptosis in RS4;11 cells carrying wild-type *p53*.** (A) Western blot analysis showing the protein expression of *MDM2*, *p53* acetylation at lysine 382, *p53*, *p21* and cleaved *PARP* measured at 6, 16 and 24 hours post doxycycline induction in the transduced RS4;11 cell line carrying doxycycline-inducible expression vectors either encoding wild-type or mutated (R248Q) *p53*. Housekeeping gene *GAPDH* was used as loading control. (B) Percentage of viable and apoptotic cells in RS4;11 cells carrying no vector (parental) or wild-type *p53*, at 24 hours post-*p53* induction by doxycycline determined by flow cytometric analysis of the Annexin V/7AAD staining. (C) Percentage of dead cells and (D) percentage of viable cells, measured by a manual cell count of Trypan Blue positive cells RS4;11 cells and Trypan Blue negative RS4;11 cells carrying either no vector (parental) or wild-type *p53*, measured at 6, 16 and 24 hours post-*p53* induction by doxycycline. All data points are represented as the mean  $\pm$  SEM of n=3.

**Figure S5. Idasanutlin and BCL2 inhibitors act in a synergistic manner on *KMT2A-AFF1* ALL cells.** (A) *in vitro* cytotoxicity of Idasanutlin in combination with Venetoclax in RS4;11 cells (left graph) and the corresponding 3D synergy matrix (right graph). (B) *in vitro* cytotoxicity of Idasanutlin in combination with Navitoclax in RS4;11 cells (left graph) and the corresponding 3D synergy matrix (right graph). Cell viability is based on a 4-day MTT assay. Drug synergy was calculated using the Zero Interaction Potency (ZIP) scoring model in SynergyFinder [54] and normalized to the effect of Idasanutlin as single agent. Concentrations where Idasanutlin as single agent showed >70% cell toxicity on average were excluded from the synergy analysis. Data points are represented as the mean  $\pm$  SEM of n=2 independent replicates.